Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00580034 · ClinicalTrials.gov registry record · Phase 2
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
A Phase 2 study of Lymphoma and Leukemia, sponsored by David Rizzieri, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
- 1
- Study location
NCT00580034 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by David Rizzieri, MD. The registered enrollment target is 176 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00580034, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by David Rizzieri, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
- 1
- Study location
Study Summary
Allogeneic transplantation is used to treat many malignant and non-malignant diseases, though the potential toxicities of the procedure remain high. We and others have shown that a less toxic preparative regimen allows reliable allogeneic engraftment for allogeneic transplantation. The primary purpose of this treatment trial is to follow patients undergoing allogeneic transplantation for long term outcomes. The regimen used has been tested in our prior phase I / II trial which has completed accrual. The issues of engraftment and rate of graft versus host disease have been answered and our success has led to this regimen being a standard approach for less toxic allogeneic therapy.
Conditions Studied
Interventions
- DRUG Campath Purged Non-myeloablative ASCT
- PROCEDURE Donor Apheresis
Study Locations (1)
North Carolina
- Duke University Health Systems - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2003-02 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00580034
The ClinicalTrials.gov registry entry for NCT00580034 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (64% lower). The listed sponsor is David Rizzieri, MD, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Campath Purged Non-myeloablative ASCT is the first listed.
NCT00580034 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00580034 about?
NCT00580034 is a clinical study titled "Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath". Allogeneic transplantation is used to treat many malignant and non-malignant diseases, though the potential toxicities of the procedure remain high. We and others have shown that a less toxic preparative regimen allows reliable allogeneic engraftment for allogeneic transplantation. The primary purp...
What is the current status of trial NCT00580034?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2003-02. Estimated completion is 2013-04.
What conditions does trial NCT00580034 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Solid Tumors, Myeloma, Myelodysplasia.
What interventions are being tested in trial NCT00580034?
The interventions under investigation include: Campath Purged Non-myeloablative ASCT (DRUG), Donor Apheresis (PROCEDURE).
Who is sponsoring clinical trial NCT00580034?
This trial is sponsored by David Rizzieri, MD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00580034 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.